GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) analogs are increasingly being used in the treatment of type 2 diabetes. It is clear that these drugs lower blood glucose through an increase in insulin secretion and a lowering of glucagon secretion; in addition, they lower body weight and systolic blood pressure and increase heart rate. Using a new monoclonal antibody for immunohistochemistry, we detected GLP-1 receptor (GLP-1R) in important target organs in humans and monkeys. In the pancreas, GLP-1R was predominantly localized in β-cells with a markedly weaker expression in acinar cells. Pancreatic ductal epithelial cells did not express GLP-1R. In the kidney and lung, GLP-1R was exclusively expressed in smooth muscle cells in the walls of arteries and arterioles. In the heart, GLP-1R was localized in myocytes of the sinoatrial node. In the gastrointestinal tract, the highest GLP-1R expression was seen in the Brunner's gland in the duodenum, with lower level expression in parietal cells and smooth muscle cells in the muscularis externa in the stomach and in myenteric plexus neurons throughout the gut. No GLP-1R was seen in primate liver and thyroid. GLP-1R expression seen with immunohistochemistry was confirmed by functional expression using in situ ligand binding with 125I-GLP-1. In conclusion, these results give important new insight into the molecular mode of action of GLP-1 analogs by identifying the exact cellular localization of GLP-1R.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, GLP-1R is present beyond the confines of the pancreas and extends to a multitude of organs and tissues throughout the body. Its extensive distribution and involvement in diverse physiological processes emphasize the important role of GLP-1R beyond the regulation of glucose metabolism.38–40”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [38]
In the citing paper
“Nevertheless, studies using antibodies that appear to be specific for this receptor are consistent with results from gene expression studies, demonstrating staining for the GLP-1 receptor in human and primate kidney in juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“The major site of expression appears to be in the renin-expressing juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“despite only modest expression of the GLP-1 receptor in the kidney”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [74]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“This strain of mice is on a C57BL background and is derivedfromthepreviouslydescribedGLP-1Rknockoutstrain(20) custom bred by Novo Nordisk A/S at Taconic.”
MethodBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“In situ ligand binding for functional GLP-1R localization was performed as described previously, apart from the use of (125)IGLP-1 (7–36) (NEX3080; PerkinElmer) instead of (125)I-exendin (9–39) (21, 22).”
MethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“GLP-1 has been shown to inhibit gastric acid secretion and gastric motility (36), and these effects fit well with our GLP-1R IHC findings.”
ResultTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 5×
“1284 Pyke et al Immunolocalization of GLP-1R Endocrinology, April 2014, 155(4):1280–1290”
BackgroundInfluentialSelf-citationCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 4×
“The low-level GLP-1R expression in acinar cells reported in this study corresponds well with previous reports using ISLB on normal human pancreas (8, 25).”
BackgroundResultInfluentialWei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Campos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Cited by
Items 801–880 of 880
Li, X., Yu, X., Gao, Y., Zhao, W., Wang, Y., Yu, F., Fu, C., Gao, H., Cheng, M., & Li, B. (2023) · Figshare · doi:10.6084/m9.figshare.23119009
Li, X., Yu, X., Gao, Y., Zhao, W., Wang, Y., Yu, F., Fu, C., Gao, H., Cheng, M., & Li, B. (2023) · Figshare · doi:10.6084/m9.figshare.23119018
Li, X., Yu, X., Gao, Y., Zhao, W., Wang, Y., Yu, F., Fu, C., Gao, H., Cheng, M., & Li, B. (2023) · Figshare · doi:10.6084/m9.figshare.23119015
Semaglutide interferes with postnatal development of juvenile mice with compromised growthPreprint
Joly, A., Rebiffé, L., Dusabyinema, Y., Dellinger, J., Gauthier, K. C., Leulier, F., & Vadder, F. D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.06.592704
Spence, D. B., Austin, R. P., Carrol, C., Pierce, S., Richter, D. L., Chamberlain, R., & Schenck, R. C. (2024) · JBJS Journal of Orthopaedics for Physician Assistants · doi:10.2106/jbjs.jopa.24.00005 · Cited by 2
Gaur, A., Keeshen, C. M., King, M., Dirks, N., Flisher, M. F., Cummings, B. P., Huising, M. O., & Whistler, J. L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.09.607397
Mermet, M., Denom, J., Mieczkowska, A., Biggs, E. K., Gribble, F. M., Reimann, F. M., Magnan, C., Cruciani‐Guglielmacci, C., & Mabilleau, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.05.616809
The role of GLP1R gene polymorphism in diabetic nephropathy in patients with type 2 diabetes
Gomaa, A. A., Zeid, A. M., & Nagy, I. M. (2025) · Gene Reports · doi:10.1016/j.genrep.2025.102205 · Cited by 1
Stronger Together: How GLP-1 RAs and SGLT-2 Inhibitors Revolutionize Type 2 Diabetes Treatment
Sitarek, H., Tabeau, A., Prus, J., Pięta, J., Pawlik, A., Dudek, P., Łuczak, K., Ulicka, W., Chudzikowski, M., & Prokopiuk, A. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.80.59642 · Cited by 2
GLP-1 RECEPTORIŲ AGONISTŲ ĮTAKA PRIEŠIRDŽIŲ VIRPĖJIMO PREVENCIJAI
Kairaitytė, M. E., Samsone, V. G., & Barysienė, J. (2025) · Health Sciences · doi:10.35988/sm-hs.2025.195
Advances in peptide-based drug discovery
Khatri, B., Velloso, J. P. L., Shambhawi, Kan, M., & Craik, D. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00041-8
Liraglutide Increases Gastric Fundus Tonus and Reduces Food Intake in Type 2 Diabetic Rats
Carrêlo, A. C. L., Martins, B. D., Seiça, R. M. F., Ribeiro, C., Matafome, P. N., & Silva, S. (2025) · Diabetology · doi:10.3390/diabetology6090096
Glucagon-like Peptide-1 Boosts Plumbagin’s Neuroprotection Against Rotenone-Induced Motor Deficits
Verma, A., & Goyal, A. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037402724251006011830
Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension
Aguado, B., Lacoste-Palasset, T., Ruffenach, G., Bauer, F., Savale, L., Humbert, M. J. C., Montani, D., & Antigny, F. (2025) · ERJ Open Research · doi:10.1183/23120541.01479-2025
Li, X., Yu, X., Gao, Y., Zhao, W., Wang, Y., Yu, F., Fu, C., Gao, H., Cheng, M., & Li, B. (2023) · Figshare · doi:10.6084/m9.figshare.23119024
Wu, S., Lu, W., Chen, Z., Dai, Y., Chen, K., & Zhang, S. (2024) · Figshare · doi:10.6084/m9.figshare.26557475
Zhou, L., Qu, H., Yang, L., & Shou, L. (2024) · Figshare · doi:10.6084/m9.figshare.26637207
Clinical applications of GLP-1 receptor–targeted PET imaging: A disease-oriented review
Wang, Z., Hacker, M., & Li, X. (2025) · Journal of Nuclear Medicine and Molecular Imaging · doi:10.65457/jnmmi-2025-0011 · Cited by 1
Semaglutide and the Effects of Glucagon-like Peptide-1 on Vision
Rajput, R., Chakravarti, H. N., Kesavadev, J., KOVIL, R. R., & Rajput, S. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_28_25
Malinauskas, M., Stukas, D., Rysevaitė-Kyguolienė, K., Gudaitytė, R., Kupcinskas, L., Casselbrant, A., Jankauskaitė, L., & Maleckas, A. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2025.1734360 · Cited by 1
“This finding suggests that GLP-1R abundance may remain stable regardless of diabetic status, in line with earlier findings showing widespread expression of GLP-1R in the gastrointestinal tract (Pyke et al., 2014).”
β-Cell adaptation to metabolic stresses requires prolactin receptor signaling
Lee, D., Kahlon, R., Deng, J., Kluttig, K. H., Morrow, N. M., Mulvihill, E. E., & Huang, C. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00108.2025
Inkretinmimetika und Schilddrüsenkrebs: Gibt es ein Risiko?
Parzer, V. (2026) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-026-00297-7
Rezki, A. (2019) · theses.fr (ABES) · doi:10.70675/392902d9z7810z4025zb9afz3081c32bac5d
de Dreuille, B. (2023) · theses.fr (ABES) · doi:10.70675/f18619c9z4015z4041zae75z8e3c7679f344
A comprehensive review of GLP-1 and aerobic training in cardiovascular disease management
Kordi, N., Kheirandish, R., Akraminia, P., Jung, F., & Karami, S. (2025) · Clinical Hemorheology and Microcirculation · doi:10.1177/13860291251414840
“38,39 Research has shown that GLP-1R mRNA transcripts are present in RNA extracted from the human left ventricle, particularly in cardiomyocytes, 38,40 The speci fi c cellular distribution and functional relevance of a fully translated ventricular GLP-1 receptor are still not well de fi ned.”
Kristensen, J. B., Nøhr-Meldgaard, J., Pors, S. E., Norlin, J., Veidal, S. S., Bendtsen, K. M., Niss, K., Andersen, M. W., Harder, L. M., Dalhoff, M. T., et al. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00011.2026 · Cited by 1
Self-citationCho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
Potential effect of the short-acting GLP-1 agonist exenatide on copeptin in healthy adults
Baumann, S., Leibnitz, S., Atila, C., Romberg, C., Hepprich, M., Antwi, K., Christ, E., & Crain, M. C. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag006
Cardiac GLP1R gene expression: A cross-species single-cell transcriptomic analysis
Dostal, C., Ernst, M., Reiner, J., Snelling, R., Hu, C., Pokreisz, P., Kiss, A., & Podesser, B. K. (2026) · Advances in Translational Research · doi:10.1556/1661.2026.00113
Donoso, P. D. R. Q., Briones, R. F. Z., Castro, C. P. M., Narváez, D. L. B., Velasco, S. A., & Jimenez, S. N. C. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20261347
FURUHASHI-HIGUCHI, M., Yamamoto, A., Fujiki, K., Nakakuki, M., Taniguchi, I., Nomura, N., Liu, L., Kozawa, Y., Niwa, E., Sato, S., et al. (2026) · Pancreas · doi:10.1097/mpa.0000000000002661
Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review
Desai, A., Habib, H., Wahbeh, L., & Farraye, F. A. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.101023
Han, S., Shin, J., Kim, J. C., & Na, D. H. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00815-4
“Consis-tently, GLP-1R was not detected in monkey liver cells (Pyke et al. 2014).”
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Corrêa, L. M. D. A., Brandão, L., Silva, Y. R. D., Ferreira, G. D., Mazur, G. R., & Arruda, S. L. P. (2026) · Translational research · doi:10.1016/j.trsl.2026.07.001
Tian, X., Ma, X., Song, E., Li, X., Fu, W., He, H., Gao, Z., & Gao, B. (2026) · Translational research · doi:10.1016/j.trsl.2026.07.008
Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction
Vignera, S. L., & Condorelli, R. A. (2026) · Biomedicines · doi:10.3390/biomedicines14071644 · Cited by 1
“GLP-1 and GIP receptors belong to the class B G protein-coupled receptor family and are expressed not only in pancreatic islets but also in diverse tissues including the central nervous system, cardiovascular system, gastrointestinal tract, kidneys, and immune cells [9,10].”
Incretins: From Gene Expression to Secretion and Action of GLP-1 and GIP
Lobato, C. B., & Holst, J. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00004-4
Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist
Ramadurgum, P., Shah, J., Shah, E., & PALMER, B. F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1917800
“Using a validated monoclonal antibody, the GLP-1 receptor in human and monkey kidney was found exclusively in the smooth muscle of arteries and arterioles, with no expression in tubular epithelium (Pyke et al., 2014; Kawanami and Takashi, 2020).”
Kim, T., Seo, J., Kang, S., Kim, H. K., Lee, B., Lee, J., & Go, G. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02259-w
Adipose Tissue Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
Cruz, A. J. L., & Yuan, L. (2026) · Cells · doi:10.3390/cells15151377 · Cited by 1
“…receptor transcript in human adipose tissue and reported effects of GLP-1 receptor agonists on adipocyte lipolysis, adipogenesis, and inflammation in ex vivo systems [122], whereas other studies using highly specific antibodies and functional assays have found no evidence of direct signaling [123].”
The prolactin-releasing peptide system: Physiological functions and therapeutic potential in obesity
Škrlová, M., Strnadová, V., Železná, B., & Maletínská, L. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107554
Zhang, S., Liu, S., Zhou, M., Wang, J., Zhang, Y., Zhong, H., & Ning, G. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06090-6
“Incretin receptors, including GLP-1R and GIPR, are widely expressed in various extrapancreatic tissues—particularly within the nervous, cardiovascular, immune, and digestive systems—which aligns with the multiorgan regulatory roles of incretins reported in related studies [65–68].”
Zhu, K., Liu, H., He, N., Wang, H., Liu, J., Zhang, Q., & Liu, Z. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70398
“GLP-1 receptor localization studies have detected receptor expression in selected vascular smooth muscle compartments, whereas other vascular effects of GLP-1RAs may occur indirectly through endothelial, in fl ammatory, hemodynamic, or metabolic pathways 15, 16 .”
GLP-1RA pharmacokinetics and clinical effects: focus on cardiac, vascular, and glomerular structures
Barnaba, I., Massari, F., Ciccone, M. M., Caldarola, P., Campanella, C., Ricci, G., & Scicchitano, P. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2714849
Impact of glucagon-like peptide-1 receptor agonists on bone metabolism
Vadini, V., Duan, D., & Moseley, K. F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag323 · Cited by 2
Zhou, S., & Dong, L. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108369
Gómez-Maldonado, I., Rodríguez-Arana, A., Tamayo-Pinzón, A., Albornoz-Suárez, J. E., Lopez-Franco, M. J., Mejia-Manrique, J. A., Forero-Caycedo, J. J., Rojas-Rodríguez, L. C., Buitrago-Ricaurte, N., Gaviria-Carrillo, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167108
“[32,74,75] OSA: obstructive sleep apnea; GLP-1: glucagon-like peptide-1; AHI: apnea–hypopnea index; hsCRP: high-sensitivity C-reactive protein; IL-6: interleukin-6; IL-1 β : interleukin-1 beta; ROS: reactive oxygen species.”
Lechi, F., Khalil, A., Bautista, P. N., Öberg, J., Balestri, L. J. I., Eriksson, O., Eriksson, J., & Odell, L. R. (2026) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-026-00486-4
“Although GLP-1R expression in the brain is lower than in the pancreas (Pyke et al. 2014), which could limit the receptor-specific PET signal in the CNS, the lack of appreciable tracer retention in the pancreas despite its relatively high GLP-1R expression indicates that the absence of measurable in…”
NAKAGAWA, R., Watanabe, M., Kawamoto, K., Hiratsuka, M., Sasaki, T., & Sasaki, N. (2026) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70281 · Cited by 1
Jin, C. A., Many, G. M., Spurrier, C. S. R., Borsellino, P., Wheeler, M. T., Adkins, J., Snyder, M. P., Newgard, C. B., Radom‐Aizik, S., Cooper, D. M., et al. (2026) · Physiological Genomics · doi:10.1152/physiolgenomics.00171.2026
O’Brien, H., Byrne, A. J., Franciosi, A. N., & Butler, M. W. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00380-z
“GLP-1 receptors are found in several extra-pancreatic tissues including ASM, the cardiovascular system, central nervous system, renal tract, and beyond [60, 64].”
Han, Y., Shon, J., & Park, Y. J. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2728313
“GLP-1 binds to GLP-1R, which is widely distributed beyond the pancreas (Pyke et al. 2014).”
Barseghyan, L., Munir, I., Chrysafides, S., Simental, A., & Khan, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15207834
“GLP-1R is a G-protein-coupled receptor for which antibody specificity has been a recognized problem: several commonly used antibodies have failed validation in receptor-null rodent tissue, and work with an extensively validated monoclonal antibody is the reference standard [40,41].”
Fan, Y., Du, L., Luo, Q., Mei, T., Zhou, A., Liu, H., Khan, M. Q., Faxian, G., & Dong, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1932225
“Each question corresponds to the extension of a step with existing foundational evidence into the tumor context (44 – 46), but this extension has yet to be tested.”
InfluentialAllaham, L., King, B. J., Ali, F., GUPTA, I., Metuku, R., Nieto, I., Lurie, A., Amer, F. N., Reddy, R., & Alzghoul, B. N. (2026) · Lung · doi:10.1007/s00408-026-00939-2 · Cited by 1
Li, Y., Hsu, J.-T., Fu, C.-M., Liu, T.-C., Lee, Y., Wu, P.-J., Li, L., Chiou, T. T., Chiu, C.-H., Kuo, W., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19101502
Yue, H., Wang, Y., Guo, X., Sun, Y., Cheng, Y., Yan, P., Tan, Z., Han, C., & Wang, B. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118495
Álvarez‐Perea, A., Entrala, A., Palomino-Lozano, L., Mazariego, E. R., & Zambrano‐Ibarra, G. (2026) · Clinical & Experimental Allergy · doi:10.1111/cea.70442
Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial
Tuttle, K. R., Bjornstad, P., Smith, C., Pruijm, M. T., McCown, P. J., Hodgin, J. B., Cherney, D. Z. I., Belmar, N., Chacko, M. M., Das, V., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04674-2 · Cited by 2
Gholam, M. F. (2026) · Cells · doi:10.3390/cells15191813
“In contrast, validated tissue localization and later functional studies did not establish meaningful hepatocyte GLP-1R signaling [7,13].”
InfluentialThe incretin-bone axis: molecular mechanisms and clinical implications
Muscarà, A., Bellone, F., & Rossi, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1907875
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Huerta, M., Muraoka, N., Jensen, M. B., Kartha, V. K., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag732 · Cited by 4
Fan, Z., Chen, Y., Li, Y., Dong, Y., An, X., Li, J., Su, L., & Wu, D. (2026) · Microbiological Research · doi:10.1016/j.micres.2026.128749
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
Efsubaglutide Alfa: A Comprehensive Pharmacological Review
Zheng, H., Yan, R., Jiang, F., Li, Y., Prud’homme, G. J., & WANG, Q. (2026) · Clinical Pharmacokinetics · doi:10.1007/s40262-026-01713-6 · Cited by 1
Yan, Y., Xu, M., Lu, S., Liang, Z., & Shen, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-11029518/v1
Mani, P., Mohanty, M., Mathur, R., & Gupta, R. (2026) · PAIN JOINTS SPINE · doi:10.1922/pjs.16.7s.2026.1216
Simeanu, G.-M. C., Dragne, I.-G., Mitrea, A., Clenciu, D., Timofticiuc, D. C. P., Popa, A.-L., Mitroi, D. M., Pirvu, B.-F., Efrem, I. C., Glodeanu, A. D., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209372
Liu, F., Xu, Z., Wang, W., Gao, J., Changgeng, F. U., & Liu, P. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1996288
GLP-1 RECEPTOR AGONISTS AND THYROID DISEASE: FROM MECHANISM TO CLINICAL PRACTICE
Milewska, A., Bociąg, A., Kowalski, K., Marciniak, R., & Ptach, Ł. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(52).2026.6324
Pharmacological Mechanisms of Once-Weekly GLP-1 Receptor Agonists for Type 2 Diabetes Management
Ali, M. A., Das, S., Kumar, R. R., & Rabindra, K. (2026) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/26oct881
Cassano, D., Fernández, G., Cornejo, M. P., Sheybani-Deloui, S., Aguggia, J. P., Cantel, S., Fehrentz, J., Habib, A. M., Rolland, L., Ravier, M. A., et al. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124754
BindingDB Entry 50022117: Binding sites and design strategies for small molecule GLP-1R agonists.
BindingDB (2025) · UC San Diego · doi:10.7270/q2474gk6
BindingDB (2023) · UC San Diego · doi:10.7270/q2736w0v
BindingDB Entry 50018378: Cyclic tailor-made amino acids in the design of modern pharmaceuticals.
BindingDB (2024) · UC San Diego · doi:10.7270/q27d30c0
Semaglutide and cardio-renal protection: Mechanistic insights from FLOW, SELECT and the NHE3 paradox
Kabir, A., Mouree, T. Z., Das, M., & Joy, F.-U.-H. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261503097
Metadata
- Authors
- Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Department of Diabetes Structural Biology (S.R.-R.), Novo Nordisk, 2880 Bagsværd, Denmark
- Rigshospitalet (DK)
- Corresponding author
- Knudsen, Lotte Bjerre
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-04-01
- Volume
- 155
- Issue
- 4
- Pages
- 1280-1290
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1979288606
- Cited by
- 876
- References
- 37
- Citations by year
- 2026: 99 · 2025: 91 · 2024: 103 · 2023: 56 · 2022: 70 · 2021: 64 · 2020: 64 · 2019: 57 · 2018: 60 · 2017: 64 · 2016: 61 · 2015: 58 · 2014: 27
- FWCI
- 56.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Endocrinology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, receptor localization, type 2 diabetes, GLP-1 analogues, pancreatic beta cells, sinoatrial node, Brunner's glands, myenteric neurons, smooth muscle cells, kidney, heart, gastrointestinal tract, receptor expression
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Insulin Secretion, Animals, Haplorhini, Antibodies, Monoclonal, Blood Pressure, Body Weight, Cell Line, Duodenum, Glucagon, Cricetinae, Heart Rate, Humans, Insulin, Ligands, Mice, Inbred C57BL, Peptides, Protein Binding, Tissue Distribution, Transfection, Venoms, Receptors, Glucagon, Mice, Knockout, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.